These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 26293237)

  • 1. Authors' reply to Srinivas: "pharmacokinetics and tolerability of the novel oral prostacyclin IP receptor agonist selexipag".
    Kaufmann P; Dingemanse J
    Am J Cardiovasc Drugs; 2015 Oct; 15(5):373-4. PubMed ID: 26293237
    [No Abstract]   [Full Text] [Related]  

  • 2. Comment on: "pharmacokinetics and tolerability of the novel oral prostacyclin IP receptor agonist selexipag".
    Srinivas NR
    Am J Cardiovasc Drugs; 2015 Oct; 15(5):371-2. PubMed ID: 26293236
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist Selexipag.
    Kaufmann P; Okubo K; Bruderer S; Mant T; Yamada T; Dingemanse J; Mukai H
    Am J Cardiovasc Drugs; 2015 Jun; 15(3):195-203. PubMed ID: 25850750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of the novel oral prostacyclin receptor agonist selexipag in subjects with hepatic or renal impairment.
    Kaufmann P; Cruz HG; Krause A; Ulč I; Halabi A; Dingemanse J
    Br J Clin Pharmacol; 2016 Aug; 82(2):369-79. PubMed ID: 27062188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selexipag, a selective prostacyclin receptor agonist in pulmonary arterial hypertension: a pharmacology review.
    Honorato Pérez J
    Expert Rev Clin Pharmacol; 2017 Jul; 10(7):753-762. PubMed ID: 28524738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioequivalence of different dose-strength tablets of selexipag, a selective prostacyclin receptor agonist, in a multiple-dose up-titration study.
    Baldoni D; Bruderer S; Muhsen N; Dingemanse J
    Int J Clin Pharmacol Ther; 2015 Sep; 53(9):788-98. PubMed ID: 26152132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of an Orally Administered Selective Prostacyclin Receptor Agonist, Selexipag, in Japanese Patients With Pulmonary Arterial Hypertension.
    Tanabe N; Ikeda S; Tahara N; Fukuda K; Hatano M; Ito H; Nakayama T; Anzai T; Hashimoto A; Inoue T; Kajinami K; Kihara Y; Kinoshita H; Kuwahara K; Murohara T; Okazaki O; Sakai S; Satoh T; Takeda Y; Takeishi Y; Taniguchi M; Watanabe H; Yamamoto T; Yamauchi-Takihara K; Yoshioka K; Sasayama S
    Circ J; 2017 Aug; 81(9):1360-1367. PubMed ID: 28420826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple-dose up-titration study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of selexipag, an orally available selective prostacyclin receptor agonist, in healthy subjects.
    Bruderer S; Hurst N; Kaufmann P; Dingemanse J
    Pharmacology; 2014; 94(3-4):148-56. PubMed ID: 25277144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI
    Preston IR; Channick RN; Chin K; Di Scala L; Farber HW; Gaine S; Galiè N; Ghofrani HA; Hoeper MM; Lang IM; McLaughlin VV; Preiss R; Simonneau G; Sitbon O; Tapson VF; Rubin LJ
    J Heart Lung Transplant; 2018 Mar; 37(3):401-408. PubMed ID: 29096938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of vasodilation mode among selexipag (NS-304; [2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide]), its active metabolite MRE-269 and various prostacyclin receptor agonists in rat, porcine and human pulmonary arteries.
    Fuchikami C; Murakami K; Tajima K; Homan J; Kosugi K; Kuramoto K; Oka M; Kuwano K
    Eur J Pharmacol; 2017 Jan; 795():75-83. PubMed ID: 27919660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absolute oral bioavailability of selexipag, a novel oral prostacyclin IP receptor agonist.
    Kaufmann P; Hurst N; Astruc B; Dingemanse J
    Eur J Clin Pharmacol; 2017 Feb; 73(2):151-156. PubMed ID: 27885399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selexipag: a selective prostacyclin receptor agonist that does not affect rat gastric function.
    Morrison K; Ernst R; Hess P; Studer R; Clozel M
    J Pharmacol Exp Ther; 2010 Oct; 335(1):249-55. PubMed ID: 20660124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of the selective prostacyclin receptor agonist selexipag in rats, dogs and monkeys.
    Ichikawa T; Yamada T; Treiber A; Gnerre C; Nonaka K
    Xenobiotica; 2018 Feb; 48(2):186-196. PubMed ID: 28277164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation of Potential Pharmacodynamic and Pharmacokinetic Interactions Between Selexipag and Warfarin in Healthy Male Subjects.
    Bruderer S; Okubo K; Mukai H; Mant T; Dingemanse J
    Clin Ther; 2016 May; 38(5):1228-1236.e1. PubMed ID: 27063071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selexipag: An Oral and Selective IP Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension.
    Asaki T; Kuwano K; Morrison K; Gatfield J; Hamamoto T; Clozel M
    J Med Chem; 2015 Sep; 58(18):7128-37. PubMed ID: 26291199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective Prostacyclin Receptor Agonist Selexipag, in Contrast to Prostacyclin Analogs, Does Not Evoke Paradoxical Vasoconstriction of the Rat Femoral Artery.
    Morrison K; Haag F; Ernst R; Iglarz M; Clozel M
    J Pharmacol Exp Ther; 2018 Jun; 365(3):727-733. PubMed ID: 29588339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experience in Transitioning From Parenteral Prostacyclins to Selexipag in Pulmonary Arterial Hypertension.
    Parikh KS; Doerfler S; Shelburne N; Kennedy K; Whitson J; Dahhan T; Fortin T; Rajagopal S
    J Cardiovasc Pharmacol; 2020 Apr; 75(4):299-304. PubMed ID: 31934912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical pharmacology, efficacy, and safety of selexipag for the treatment of pulmonary arterial hypertension.
    Bruderer S; Hurst N; Remenova T; Dingemanse J
    Expert Opin Drug Saf; 2017 Jun; 16(6):743-751. PubMed ID: 28494686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic drug evaluation of selexipag for the treatment of pulmonary arterial hypertension.
    Sardana M; Moll M; Farber HW
    Expert Opin Drug Metab Toxicol; 2016 Dec; 12(12):1513-1520. PubMed ID: 27756196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The metabolism and drug-drug interaction potential of the selective prostacyclin receptor agonist selexipag.
    Gnerre C; Segrestaa J; Seeland S; Äänismaa P; Pfeifer T; Delahaye S; de Kanter R; Ichikawa T; Yamada T; Treiber A
    Xenobiotica; 2018 Jul; 48(7):704-719. PubMed ID: 28737453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.